Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | CCNC | P24863 | 2/20 | 0.32 |
| ▸ | CDK8 | P49336 | 2/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115199 | 0.84 | KDM4E (0.35) | PIK3CAMTORPIK3CDPIK3CGCCNC | |
| SCHEMBL1115156 | 0.81 | PIK3CA (0.34) | PIK3CAMTORPIK3CDPIK3CGALOX5AP | |
| SCHEMBL1643495 | 0.73 | ALDH1A1 (0.36) | ALOX5APDHFRADORA1ADORA2AKDM4E | |
| SCHEMBL1642247 | 0.73 | ALDH1A1 (0.36) | ALOX5APDHFRADORA1ADORA2AKDM4E | |
| SCHEMBL1115345 | 0.72 | DHFR (0.33) | PIK3CAMTORPIK3CDPIK3CGALOX5AP | |
| SCHEMBL1643196 | 0.72 | ALDH1A1 (0.37) | ALOX5APDHFRADORA1ADORA2AKDM4E | |
| SCHEMBL12769437 | 0.70 | S1PR1 (0.35) | ALOX5APADORA1ADORA2AKDM4EALDH1A1 | |
| SCHEMBL1115314 | 0.70 | ALK (0.41) | — | |
| SCHEMBL1115194 | 0.69 | ALOX5AP (0.31) | ALOX5AP | |
| SCHEMBL1115148 | 0.68 | ALOX5AP (0.34) | PIK3CAMTORPIK3CDPIK3CGALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2278973-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | CDK4, CDK3, CDK6 | PIK3CA 356/4885MTOR 208/4885PIK3CD 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.